# Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

> **NCT02483000** · PHASE1 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Burkitt Lymphoma
- CD20-Positive Neoplastic Cells Present
- Diffuse Large B-Cell Lymphoma
- Indolent Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Refractory Mature B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carmustine
- **DRUG:** Clearing Agent
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **RADIATION:** Indium In 111-DOTA-Biotin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Pharmacological Study
- **RADIATION:** Yttrium Y 90-DOTA-Biotin

## Key facts

- **NCT ID:** NCT02483000
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-01
- **Primary completion:** 2019-11-17
- **Final completion:** 2020-09-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Closed early due to lack of funding
- **Last updated:** 2020-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483000, "Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02483000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*